Cancer Res Treat.  2023 Oct;55(4):1063-1064. 10.4143/crt.2023.780.

Barriers in Oligometastasis Care in Korea: Radiation Oncologists’ Perspectives

• Chie EK
• Rim CH
• Cho WK
• Ahn YC

• KMID: 2547780
• DOI: http://doi.org/10.4143/crt.2023.780

Reference

References

1. Cho WK. Customized RT in oligometastasis. In : 49th Annual Meeting of Korean Cancer Association & 9th International Cancer Conference; 2023 Jun 15–16; Seoul, Korea.

2. Cho WK, Yoo GS, Rim CH, Jeong JU, Chie EK, Ahn YC, et al. Differential perspectives by specialty on oligometastatic colorectal cancer: a Korean-Oligometastasis Working Group’s comparative survey study. Cancer Res Treat. 2023; 55:1281–90.

3. Guckenberger M, Lievens Y, Bouma AB, Collette L, Dekker A, deSouza NM, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020; 21:e18–28.

4. Ministry of Health and Welfare. National health insurance, act No. 32748 (2022 Jun 30). Republic of Korea.

5. Ministry of Health and Welfare. Enforcement decree of the national health insurance, act No. 18895 (2022 Jun 10). Republic of Korea.

6. Sebastian NT, Xu-Welliver M, Williams TM. Stereotactic body radiation therapy (SBRT) for early stage non-small cell lung cancer (NSCLC): contemporary insights and advances. J Thorac Dis. 2018; 10:S2451–64.

7. Zeng KL, Tseng CL, Soliman H, Weiss Y, Sahgal A, Myrehaug S. Stereotactic body radiotherapy (SBRT) for oligometastatic spine metastases: an overview. Front Oncol. 2019; 9:337.

8. Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J Clin Oncol. 2020; 38:2830–8.

9. Rim CH, Cho WK, Lee JH, Kim YS, Suh YG, Kim KH, et al. Role of local treatment for oligometastasis: a comparability-based meta-analysis. Cancer Res Treat. 2022; 54:953–69.

10. Tan VS, Palma DA. Top ten lessons learned from trials in oligometastatic cancers. Cancer Res Treat. 2023; 55:5–14.